Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

This 2020 electron microscope image made available by the U.S. Centers for Disease Control and Prevention shows the spherical particles of the new coronavirus, colorized blue, from the first U.S. case of COVID-19.

Hannah A. BullockAzaibi Tamin/The Canadian Press

From vitamin D to the disease-fighting potential of sewage, the latest research funded by Ottawa shows how rapidly the science surrounding COVID-19 is evolving.

On Thursday, the federal government announced which projects have been selected for funding in its largest competition yet for pandemic-related research. Compared to the results of an earlier funding call in February, the list reflects a health crisis that has progressed from being a hypothetical threat to a daily reality affecting the life and work of most Canadians.

Drawn from a pool for 1,488 proposals, the winning projects will split more than $109-million in funding, allocated last April as part of the federal government’s COVID-19 response strategy.

Story continues below advertisement

“It’s a balanced portfolio when you think about what we need to be doing against the virus,” said Michael Strong, president of the Canadian Institutes for Health Research, the federal agency that oversaw the competition.

There is another way in which the new phase of funding is more balanced than the first, Dr. Strong said. This time around, 44 per cent of the successful applicants are women.

Results of the earlier round appeared to favour male researchers. The agency then realized that female researchers have generally been experiencing greater disruptions to their work because of the pandemic, Dr. Strong said, including by bearing the brunt of the pandemic’s impact on family life. This left many with less time to prepare grant applications.

“It wasn’t a level playing field,” he added. During the second competition researchers were allowed 10 additional days to submit their proposals, a change that appears to have corrected the problem.

More than 1,000 reviewers were involved in judging the projects on their scientific merits. Proposals were grouped into five categories:


Several treatment options for COVID-19 are being explored by projects in this category, which includes the largest single grant of $4.2-million, awarded to a study led by Francine Ducharme, a clinical researcher at Montreal’s Sainte-Justine hospital. Starting in September, Dr. Ducharme will conduct a randomized trial, based on preliminary evidence, to test if vitamin D acts as a deterrent to infection when administered in high doses to thousands of health care workers.

“This is the only study worldwide looking at primary prevention [using vitamin D],” she said.

Story continues below advertisement


When the pandemic hit, John Lewis and his colleagues at the University of Alberta realized they could repurpose a system for introducing DNA into cells that they developed as a cancer therapy to instead train the immune system to fight COVID-19. Dr. Lewis’s approach includes an innovation originally developed at Dalhousie University in Halifax that makes it easier to open up a portal into a cell and slip the DNA in. With $4.1-million in federal funding, his aim is to advance the strategy to human clinical trials as early as August, he said.


In this round there were fewer projects funded that involved diagnostics tests to spot COVID-19 infections, which is now becoming routine. One exception is a proposal by Yingfu Li, a biochemist at McMaster University in Hamilton, who has been awarded $1.3-million to develop a test using saliva that does not require specialized laboratory equipment. Such a test could be performed at a school, workplace or home – offering a significant advantage in the effort to detect emerging outbreaks.

Social policy and public-health responses

The most wide-ranging category includes an effort by Michael Parkins, an infectious-disease researcher at the University of Calgary, to test waste water in the city’s sewers in order to spot where new outbreaks may be emerging at the neighbourhood level. The data could give public-health officials the heads-up to respond and to focus measures where they are most needed. Lori Wilkinson, a sociologist at the University of Manitoba, will use her funding to study the adverse effects of the pandemic on First Nation, immigrant and other communities in Canada, the United States and Mexico. Both projects are funded at the half-million-dollar level.

Clinical management and health system interventions

Corinne Hohl, who is both an emergency room physician and a researcher at the University of British Columbia, is leading a $2.1-million study that exemplifies this category. By drawing on data from 51 emergency departments across eight provinces, her goal is to better guide the on-the-spot decisions that are made when COVID-19 patients are admitted to hospital. Dr. Hohl said the project would be moving quickly to ramp up data collection on as many as 100,000 cases.

“Hopefully we can be ready for a fall wave – which I hope doesn’t come,” she said.

Sign up for the Coronavirus Update newsletter to read the day’s essential coronavirus news, features and explainers written by Globe reporters and editors.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies